Q Chip Ltd announces appointment of Tony Mills
Advertisement
Q Chip Ltd announced that it has appointed Dr Tony mills to its Board of Directors. Tony brings a wealth of experience in commercialising technology in the biopharmaceutical sector and as Chief Commercial Officer, will be responsible for generating revenues from Q Chip’s proprietary technology, Q-SpheraTM.
Tony has over 20 years experience in intellectual property (IP) management and biotech commercialisation. After training as a virologist he worked in the vaccine industry for several years before joining the IP development company, BTG, where he licensed vaccine related IP worldwide. Tony was a key member of the team that founded Peptide Therapeutics, acquired as Acambis in 2008 by Sanofi Aventis for £280 million. More recently Tony has continued his interest in the commercialisation of biotech as VP Business Development at BioVex, followed by a role as an Executive Director of Phynova, the Oxford based company deriving novel drug candidates from plants.